Literature DB >> 29286484

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells.

Sriram Vijayraghavan1, Boris Kantor2.   

Abstract

Lentiviral vectors are an ideal choice for delivering gene-editing components to cells due to their capacity for stably transducing a broad range of cells and mediating high levels of gene expression. However, their ability to integrate into the host cell genome enhances the risk of insertional mutagenicity and thus raises safety concerns and limits their usage in clinical settings. Further, the persistent expression of gene-editing components delivered by these integration-competent lentiviral vectors (ICLVs) increases the probability of promiscuous gene targeting. As an alternative, a new generation of integrase-deficient lentiviral vectors (IDLVs) has been developed that addresses many of these concerns. Here the production protocol of a new and improved IDLV platform for CRISPR-mediated gene editing and list the steps involved in the purification and concentration of such vectors is described and their transduction and gene-editing efficiency using HEK-293T cells was demonstrated. This protocol is easily scalable and can be used to generate high titer IDLVs that are capable of transducing cells in vitro and in vivo. Moreover, this protocol can be easily adapted for the production of ICLVs.

Mesh:

Substances:

Year:  2017        PMID: 29286484      PMCID: PMC5755554          DOI: 10.3791/56915

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  40 in total

1.  Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.

Authors:  Wenqin Xu; Jill L Russ; Maribeth V Eiden
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Delivery of Genome Editing Reagents to Hematopoietic Stem/Progenitor Cells.

Authors:  Megan D Hoban; Zulema Romero; Gregory J Cost; Matthew Mendel; Michael Holmes; Donald B Kohn
Journal:  Curr Protoc Stem Cell Biol       Date:  2016-02-03

3.  Genome-scale CRISPR-Cas9 knockout screening in human cells.

Authors:  Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

4.  CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.

Authors:  Lei Xu; Huan Yang; Yang Gao; Zeyu Chen; Liangfu Xie; Yulin Liu; Ying Liu; Xiaobao Wang; Hanwei Li; Weifeng Lai; Yuan He; Anzhi Yao; Liying Ma; Yiming Shao; Bin Zhang; Chengyan Wang; Hu Chen; Hongkui Deng
Journal:  Mol Ther       Date:  2017-05-17       Impact factor: 11.454

5.  The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter.

Authors:  M Gómez-Gonzalo; M Carretero; J Rullas; E Lara-Pezzi; J Aramburu; B Berkhout; J Alcamí; M López-Cabrera
Journal:  J Biol Chem       Date:  2001-07-16       Impact factor: 5.157

6.  Artificial zinc finger fusions targeting Sp1-binding sites and the trans-activator-responsive element potently repress transcription and replication of HIV-1.

Authors:  Yeon-Soo Kim; Jung-Min Kim; Deug-Lim Jung; Jae-Eun Kang; Sukyung Lee; Jin Soo Kim; Wongi Seol; Hyun-Chul Shin; Heung Sun Kwon; Carine Van Lint; Nouria Hernandez; Man-Wook Hur
Journal:  J Biol Chem       Date:  2005-03-02       Impact factor: 5.157

7.  A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector.

Authors:  Matthew Bayer; Boris Kantor; Adam Cockrell; Hong Ma; Brian Zeithaml; Xiangping Li; Thomas McCown; Tal Kafri
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

8.  CFTR inactivation by lentiviral vector-mediated RNA interference and CRISPR-Cas9 genome editing in human airway epithelial cells.

Authors:  Jessica Bellec; Marc Bacchetta; Davide Losa; Ignacio Anegon; Marc Chanson; Tuan Huy Nguyen
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

9.  Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors.

Authors:  Diana E Jaalouk; Milena Crosato; Pnina Brodt; Jacques Galipeau
Journal:  Virol J       Date:  2006-04-07       Impact factor: 4.099

10.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

View more
  8 in total

1.  Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.

Authors:  Boris Kantor; Lidia Tagliafierro; Jeffrey Gu; Madison E Zamora; Ekaterina Ilich; Carole Grenier; Zhiqing Y Huang; Susan Murphy; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2018-08-29       Impact factor: 11.454

2.  An Adaptive Real-Time 3D Single Particle Tracking Method for Monitoring Viral First Contacts.

Authors:  Shangguo Hou; Kevin Welsher
Journal:  Small       Date:  2019-09-17       Impact factor: 13.281

3.  Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models.

Authors:  Lidia Tagliafierro; Ekaterina Ilich; Malik Moncalvo; Jeffrey Gu; Ahila Sriskanda; Carole Grenier; Susan K Murphy; Ornit Chiba-Falek; Boris Kantor
Journal:  J Vis Exp       Date:  2019-03-29       Impact factor: 1.355

4.  Design and Synthesis of Bovine Leukemia Virus-Associated Peptide-Based Qβ Conjugate Eliciting Long-Lasting Neutralizing Antibodies in Mice.

Authors:  Shivangi Chugh; Cheryl Swenson; Vilma Yuzbasiyan-Gurkan; Xuefei Huang
Journal:  ACS Infect Dis       Date:  2022-04-28       Impact factor: 5.578

5.  An Improved Protocol for the Production of Lentiviral Vectors.

Authors:  Logan Y Brown; Wendy Dong; Boris Kantor
Journal:  STAR Protoc       Date:  2020-10-27

6.  Gene-Editing Technologies Paired With Viral Vectors for Translational Research Into Neurodegenerative Diseases.

Authors:  Joseph Edward Rittiner; Malik Moncalvo; Ornit Chiba-Falek; Boris Kantor
Journal:  Front Mol Neurosci       Date:  2020-08-12       Impact factor: 5.639

7.  Integrase deficient lentiviral vector: prospects for safe clinical applications.

Authors:  Chee-Hong Takahiro Yew; Narmatha Gurumoorthy; Fazlina Nordin; Gee Jun Tye; Wan Safwani Wan Kamarul Zaman; Jun Jie Tan; Min Hwei Ng
Journal:  PeerJ       Date:  2022-08-12       Impact factor: 3.061

Review 8.  Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.

Authors:  Wendy Dong; Boris Kantor
Journal:  Viruses       Date:  2021-07-01       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.